256 related articles for article (PubMed ID: 37409127)
1. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
3. Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension.
Diekmann F; Chouvarine P; Sallmon H; Meyer-Kobbe L; Kieslich M; Plouffe BD; Murthy SK; Lichtinghagen R; Legchenko E; Hansmann G
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445297
[TBL] [Abstract][Full Text] [Related]
4. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis.
Becker MO; Radic M; Schmidt K; Huscher D; Riedlinger A; Michelfelder M; Meisel C; Ewert R; Burmester GR; Riemekasten G
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(4):274-284. PubMed ID: 32476963
[TBL] [Abstract][Full Text] [Related]
7. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
8. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
9. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
10. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
[TBL] [Abstract][Full Text] [Related]
11. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis.
Fairley JL; Hansen D; Ross L; Proudman S; Sahhar J; Ngian GS; Walker J; Host LV; Morrisroe K; Apostolopoulous D; Ferdowsi N; Wilson M; Tabesh M; Stevens W; Nikpour M;
Arthritis Res Ther; 2023 May; 25(1):77. PubMed ID: 37173780
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.
Yoshizaki A; Komura K; Iwata Y; Ogawa F; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Clin Immunol; 2009 Mar; 29(2):180-9. PubMed ID: 18825489
[TBL] [Abstract][Full Text] [Related]
14. Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study.
Sarı A; Satış H; Ayan G; Küçükşahin O; Kalyoncu U; Fidancı AA; Ayvalı MO; Ata N; Ülgü MM; Birinci Ş; Akdoğan A
Clin Rheumatol; 2024 Jun; 43(6):1919-1925. PubMed ID: 38676757
[TBL] [Abstract][Full Text] [Related]
15. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
[TBL] [Abstract][Full Text] [Related]
16. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
[TBL] [Abstract][Full Text] [Related]
17. RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertension.
Jia D; He Y; Zhu Q; Liu H; Zuo C; Chen G; Yu Y; Lu A
Cardiovasc Res; 2017 May; 113(6):586-597. PubMed ID: 28407046
[TBL] [Abstract][Full Text] [Related]
18. Soluble receptor for advanced glycation end-products and progression of airway disease.
Iwamoto H; Gao J; Pulkkinen V; Toljamo T; Nieminen P; Mazur W
BMC Pulm Med; 2014 Apr; 14():68. PubMed ID: 24758342
[TBL] [Abstract][Full Text] [Related]
19. Survival after lung transplantation in systemic sclerosis. A systematic review.
Khan IY; Singer LG; de Perrot M; Granton JT; Keshavjee S; Chau C; Kron A; Johnson SR
Respir Med; 2013 Dec; 107(12):2081-7. PubMed ID: 24113572
[TBL] [Abstract][Full Text] [Related]
20. The relevance of high-resolution computed tomographic findings and pulmonary arterial hypertension in systemic sclerosis-associated interstitial lung disease.
Wangkaew S; Euathrongchit J; Patiwetwitoon S; Prasertwitayakij N; Kasitanon N; Louthrenoo W
J Med Assoc Thai; 2014 Aug; 97(8):878-85. PubMed ID: 25345265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
